Centerpulse Divestitures Could Make Remaining Firm Attractive To Acquirers
This article was originally published in The Gray Sheet
Executive Summary
Centerpulse's plan to divest its cardiac and vascular divisions to focus on its core orthopedics business suggests that the Swiss firm may be positioning itself for an eventual sale to a larger player in that arena
You may also be interested in...
Centerpulse Divestiture Plan Complete With Sale Of Heart Valve Biz To Snia
Centerpulse's exit from the cardiovascular market is complete with the Nov. 27 sale of its Carbomedics and Mitroflow mechanical and tissue heart valve units to Milan-based Snia
Centerpulse Divestiture Plan Complete With Sale Of Heart Valve Biz To Snia
Centerpulse's exit from the cardiovascular market is complete with the Nov. 27 sale of its Carbomedics and Mitroflow mechanical and tissue heart valve units to Milan-based Snia
ev3 Expanding Vascular Presence Via $95 Mil. IntraTherapeutics Acquisition
Private equity investor Warburg Pincus' ev3, Inc. unit is looking to build its peripheral vascular disease business through the purchase of Centerpulse subsidiary IntraTherapeutics for $95 mil. cash